- Definition

Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.

+ References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Additional Milestones Payment Receivable

+ References

No definition available.

+ Details

Name:	inpha_AdditionalMilestonesPaymentReceivable
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Additional Milestones Payment Receivable, Not Eligible

+ References

No definition available.

+ Details

Name:	inpha_AdditionalMilestonesPaymentReceivableNotEligible
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The co-fund percentage of trials of licensed product.

+ References

No definition available.

+ Details

Name:	inpha_CoFundPercentageOfTrialsOfLicensedProduct
Namespace Prefix:	inpha_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The commercialization milestones pursuant to the agreement.

+ References

No definition available.

+ Details

Name:	inpha_CommercializationMilestones
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The development and regulatory milestones pursuant to the agreement.

+ References

No definition available.

+ Details

Name:	inpha_DevelopmentAndRegulatoryMilestones
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The maximum amount that receivable from counter party upon achievement of certain development and regulatory milestones and commercialization milestones.

+ References

No definition available.

+ Details

Name:	inpha_MaximumAmountReceivableFromCounterPartyUponAchievementOfCertainMilestones
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum Potential Regulatory Milestones

+ References

No definition available.

+ Details

Name:	inpha_MaximumPotentialRegulatoryMilestones
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The percentage of profits in Europe.

+ References

No definition available.

+ Details

Name:	inpha_PercentageOfProfitsInEurope
Namespace Prefix:	inpha_
Data Type:	dtr-types1:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from the exercise of option agreement.

+ References

No definition available.

+ Details

Name:	inpha_ProceedsFromExerciseOfOptionAgreement
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from co-development agreement.

+ References

No definition available.

+ Details

Name:	inpha_ReceiptsFromCodevelopmentAgreement
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from co-development agreement and option agreement.

+ References

No definition available.

+ Details

Name:	inpha_ReceiptsFromCodevelopmentAgreementAndOptionAgreement
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash inflow from option agreement.

+ References

No definition available.

+ Details

Name:	inpha_ReceiptsFromOptionAgreement
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue From Contracts With Customers, Milestone Payment Received

+ References

No definition available.

+ Details

Name:	inpha_RevenueFromContractsWithCustomersMilestonePaymentReceived
Namespace Prefix:	inpha_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	ifrs-full_TypesOfContractsAxis=inpha_A2015AstraZenecaMonalizumabAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

The company - 2015 AstraZeneca monalizumab agreements (Details) - 2015 monalizumab agreement, with AstraZeneca € in Millions, $ in Millions					1 Months Ended
	Aug. 01, 2022 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 EUR (€)	Dec. 07, 2020 USD ($)	Jun. 30, 2022 USD ($)	Oct. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jan. 31, 2019 USD ($)	Jun. 30, 2015 USD ($)
Disclosure of disaggregation of revenue from contracts with customers [line items]
Receipts from co-development agreement and option agreement									$ 250.0
Receipts from co-development agreement									100.0
Receipts from option agreement									150.0
Proceeds from exercise of option agreement								$ 100.0
Maximum potential regulatory milestones									100.0
Milestone payment received		$ 50.0	€ 47.7	$ 50.0	$ 50.0	$ 50.0
Additional milestones payment receivable							$ 50.0
Additional milestones payment, not eligible	$ 50.0
Maximum amount receivable from counter party upon achievement of certain milestones									775.0
Development and regulatory milestones									350.0
Commercialization milestones									$ 425.0
Co-fund percentage of trials of licensed product									30.00%
Percentage of profits in Europe									50.00%